Stock Events

Stock Events

Crescent Biopharma 

$18.17
38
-$0.93-4.87% Friday 20:00

Statistics

Day High
19.07
Day Low
18.1
52W High
29
52W Low
8.72
Volume
154,251
Avg. Volume
211,370
Mkt Cap
1.75B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jan 23
$24
Sep 22
$143
Aug 15
$56.92
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

8MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.06
-0.03
0.01
0.05
Expected EPS
-0.0625383824
Actual EPS
N/A

Financials

11.43%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
211.51MRevenue
24.17MNet Income

Analyst Ratings

$28.50Average Price Target
The highest estimate is 35.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CBIO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics works on genomic medicines for genetic diseases, potentially competing in the same therapeutic areas as GlycoMimetics.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is involved in gene editing for genetic diseases, which could compete with GlycoMimetics' drug development programs.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals develops treatments for cystic fibrosis and other serious diseases, competing in the broader market for rare diseases.
Novartis
NVS
Mkt Cap297.32B
Novartis offers a wide range of pharmaceutical products, including treatments for conditions that GlycoMimetics targets.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing in the rare disease space with GlycoMimetics.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for genetic diseases, potentially competing with GlycoMimetics' therapeutic approaches.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics develops RNA-based therapeutics for rare diseases, which could compete with GlycoMimetics' products.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotechnology company with a broad portfolio, including treatments for conditions that GlycoMimetics may target.

About

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Show more...
CEO
Mr. Joshua T. Brumm
Employees
41
Country
US
ISIN
KYG2545C1042

Listings

F
DE
C68.F
STU
DE
C68.STU
XNAS
US
CBIO
BOATS
BOATS
CBIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Crescent Biopharma stock price today?▼
The current price of CBIO is $18.17 USD — it has decreased by -4.87% in the past 24 hours. Watch Crescent Biopharma stock price performance more closely on the chart.
What is Crescent Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Crescent Biopharma stocks are traded under the ticker CBIO.
What is Crescent Biopharma market cap?▼
Today Crescent Biopharma has the market capitalization of 1.75B
When is the next Crescent Biopharma earnings date?▼
Crescent Biopharma is going to release the next earnings report on April 30, 2026.
What were Crescent Biopharma earnings last quarter?▼
CBIO earnings for the last quarter are -4.01 USD per share, whereas the estimation was -2.47 USD resulting in a -62.25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Crescent Biopharma revenue for the last year?▼
Crescent Biopharma revenue for the last year amounts to 211.51M USD.
What is Crescent Biopharma net income for the last year?▼
CBIO net income for the last year is 24.17M USD.
Does Crescent Biopharma pay dividends?▼
Yes, CBIO dividends are paid monthly. The last dividend per share was 3.6 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Crescent Biopharma have?▼
As of April 11, 2026, the company has 41 employees.
In which sector is Crescent Biopharma located?▼
Crescent Biopharma operates in the Health Care sector.
When did Crescent Biopharma complete a stock split?▼
The last stock split for Crescent Biopharma was on June 16, 2025 with a ratio of 1:100.
Where is Crescent Biopharma headquartered?▼
Crescent Biopharma is headquartered in Waltham, US.